Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 10, 2026, 6:15 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 90 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Community-acquired Pneumonia Clear all
Completed Phase 4 Interventional

Safety and Efficacy Study of Ceftaroline Versus a Comparator in Pediatric Subjects With Complicated Community Acquired Pneumonia (CABP)

NCT01669980
View directory record Official record
Conditions
Infections, Pneumonia
Interventions
Ceftaroline fosamil, IV Ceftriaxone and Vancomycin
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
2 Months to 18 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
13
States / cities
Long Beach, California • Oakland, California • Orange County, California + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2015 · Synced Jun 10, 2026, 6:15 PM EDT
Completed Phase 2 Interventional

A Safety and Efficacy Study of Hospitalized Patients With Community-Acquired Pneumonia and Sepsis

NCT00042588
View directory record Official record
Conditions
Pneumonia, Sepsis
Interventions
Recombinant Chimeric Monoclonal Antibody
Drug
Lead sponsor
ICOS Corporation
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
1
States / cities
Bothell, Washington
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Jun 10, 2026, 6:15 PM EDT
Terminated Phase 4 Interventional Results available

Efficacy Study of Fluconazole to Treat Coccidioidomycosis Pneumonia (Valley Fever)

NCT02663674
View directory record Official record
Conditions
Coccidioidomycosis
Interventions
Fluconazole, Placebo
Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 99 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
9
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 4, 2019 · Synced Jun 10, 2026, 6:15 PM EDT
Active, not recruiting Not applicable Interventional

Discharge Stewardship in Children's Hospitals

NCT05826873
View directory record Official record
Conditions
Pneumonia, Bacterial, Pneumonia Childhood, Urinary Tract Infections, Soft Tissue Infections, Skin Infections, Community-acquired Pneumonia
Interventions
Discharge antibiotic stewardship intervention
Behavioral
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
28 Days to 18 Years
Enrollment
1,131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
5
States / cities
St Louis, Missouri • Philadelphia, Pennsylvania • Salt Lake City, Utah + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2026 · Synced Jun 10, 2026, 6:15 PM EDT
Terminated Phase 4 Interventional

Study Comparing the Clinical Efficacy and Health Outcomes of Outpatients With Mild to Moderate Community-Acquired Pneumonia (CAP) Treated With Either Telithromycin Once Daily for 7 Days, or Azithromycin Once Daily for 5 Days

NCT00237445
View directory record Official record
Conditions
Pneumonia
Interventions
telithromycin, azithromycin
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 10, 2011 · Synced Jun 10, 2026, 6:15 PM EDT
Terminated Phase 3 Interventional Results available

Reparixin add-on Therapy to Standard Care to Limit Progression in Pts With COVID19 & Other Community Acquired Pneumonia

NCT05254990
View directory record Official record
Conditions
Infectious Pneumonia, Severe COVID-19
Interventions
Reparixin, Placebo
Drug · Other
Lead sponsor
Dompé Farmaceutici S.p.A
Industry
Eligibility
18 Years and older
Enrollment
414 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
28
States / cities
Tucson, Arizona • Orange, California • Denver, Colorado + 24 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2026 · Synced Jun 10, 2026, 6:15 PM EDT
Terminated Phase 1 Interventional

A Clinical Safety Study on AT-100 in Treating Adults With Severe COVID-19 Infection or Severed Community Acquired Pneumonia

NCT04659122
View directory record Official record
Conditions
COVID-19, Undefined
Interventions
AT-100
Biological
Lead sponsor
Airway Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 13, 2023 · Synced Jun 10, 2026, 6:15 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Non-invasive Biometric Monitoring in Nursing Homes to Fight COVID-19

NCT04548895
View directory record Official record
Conditions
Covid19, Community-Acquired Respiratory Tract Infection
Interventions
Observational measurement of biometric data. No change to health care provided.
Device
Lead sponsor
Health Stream Analytics, LLC
Industry
Eligibility
Not listed
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Pasco, Washington
Source: ClinicalTrials.gov public record
Updated Jun 10, 2021 · Synced Jun 10, 2026, 6:15 PM EDT
Withdrawn Phase 4 Interventional

Impact of Statins on Cytokine Expression in Pneumonia

NCT00946166
View directory record Official record
Conditions
Community Acquired Pneumonia, Cardiovascular Risk Factors
Interventions
simvastatin, Placebo
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 21, 2015 · Synced Jun 10, 2026, 6:15 PM EDT
Not listed No phase listed Observational

Observational Study of Sepsis and Pneumonia to Develop Diagnostic Tests

NCT00258869
View directory record Official record
Conditions
Sepsis, Septicemia, Sepsis Syndrome, Shock, Septic, Community Acquired Pneumonia
Interventions
Not listed
Lead sponsor
National Center for Genome Resources
Other
Eligibility
6 Years and older
Enrollment
1,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
3
States / cities
Detroit, Michigan • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 8, 2010 · Synced Jun 10, 2026, 6:15 PM EDT
Terminated Phase 2 Interventional Results available

Ticagrelor in Severe Community Acquired Pneumonia

NCT01998399
View directory record Official record
Conditions
Community Acquired Pneumonia, Severe
Interventions
Ticagrelor, Placebo
Drug
Lead sponsor
Gordon Bernard
Other
Eligibility
50 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
26
States / cities
Tucson, Arizona • Colorado Springs, Colorado • Denver, Colorado + 19 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2017 · Synced Jun 10, 2026, 6:15 PM EDT
Completed Phase 3 Interventional

Efficacy and Safety Study of Oral Solithromycin (CEM-101) Compared to Oral Moxifloxacin in Treatment of Patients With Community-Acquired Bacterial Pneumonia

NCT01756339
View directory record Official record
Conditions
Community-acquired Bacterial Pneumonia
Interventions
Solithromycin, Moxifloxacin, Placebo to match solithromycin
Drug · Other
Lead sponsor
Melinta Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
860 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
25
States / cities
Glendale, California • Los Angeles, California • Mission Hills, California + 18 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2017 · Synced Jun 10, 2026, 6:15 PM EDT
Completed Not applicable Interventional Results available

Using Electronically Derived Automated Reports of Appropriate Antibiotic Use to Inform Stewardship Interventions

NCT06027593
View directory record Official record
Conditions
Community-acquired Pneumonia, Acute Otitis Media, Pharyngitis
Interventions
Quasi experimental intervention
Other
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
Not listed
Enrollment
26,139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
2
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 13, 2025 · Synced Jun 10, 2026, 6:15 PM EDT
Recruiting Not applicable Interventional

Comparing Antibiotic Treatment Strategies for Children With Pneumonia in Outpatient Settings: (STAMPP)

NCT06986148
View directory record Official record
Conditions
Community Acquired Pneumonia (CAP), Community Acquired Pneumonia
Interventions
Immediate Antibiotic Prescribing Group Instructions, Safety Net Antibiotic Prescribing (SNAP) Group Instructions
Other
Lead sponsor
Ann & Robert H Lurie Children's Hospital of Chicago
Other
Eligibility
12 Months to 71 Months
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
4
States / cities
Atlanta, Georgia • Chicago, Illinois • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2026 · Synced Jun 10, 2026, 6:15 PM EDT
Completed Not applicable Interventional

Outcomes of Patients Not Responding to Antibiotics in the Community

NCT00245427
View directory record Official record
Conditions
Sinusitis, Bronchitis, Chronic, Pneumonia, Bacterial
Interventions
all macrolide antibiotics, all beta-lactam antibiotics
Drug
Lead sponsor
CPL Associates
Other
Eligibility
Up to 95 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Spokane, Washington
Source: ClinicalTrials.gov public record
Updated Oct 30, 2007 · Synced Jun 10, 2026, 6:15 PM EDT
Completed Phase 4 Interventional

Avelox for Treatment of Elderly Patients With Community Acquired Pneumonia

NCT00665327
View directory record Official record
Conditions
Pneumonia
Interventions
Avelox (Moxifloxacin, BAY12-8039), Levofloxacin
Drug
Lead sponsor
Bayer
Industry
Eligibility
65 Years and older
Enrollment
401 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
76
States / cities
Mobile, Alabama • Tucson, Arizona • Brea, California + 64 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2014 · Synced Jun 10, 2026, 6:15 PM EDT
Completed Phase 1 Interventional

Targeting Platelet-Leukocyte Aggregates in Pneumonia With Ticagrelor

NCT01883869
View directory record Official record
Conditions
Pneumonia, Community Acquired Pneumonia, Hospital Acquired Pneumonia, Acute Lung Injury
Interventions
ticagrelor, placebo
Drug
Lead sponsor
University of Kentucky
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
2
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Sep 12, 2018 · Synced Jun 10, 2026, 6:15 PM EDT
Completed No phase listed Observational

Community Acquired Pneumonia in Older Adults

NCT04709978
View directory record Official record
Conditions
Pneumonia, Aspiration Pneumonia
Interventions
Videofluoroscopic Swallowing Study, Nuclear medicine pulmonary aspiration study, TOR-BSST and 3 oz Water Swallow, Sputum Culture, MeMed BV®, Lung Ultrasound, Respiratory Function Tests
Diagnostic Test
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
60 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 14, 2023 · Synced Jun 10, 2026, 6:15 PM EDT
Terminated Phase 2 Interventional

Safety and Efficacy Study of Oral Zabofloxacin in Community Acquired Pneumonia

NCT01081964
View directory record Official record
Conditions
Community Acquired Pneumonia
Interventions
Zabofloxacin, Levofloxacin 500mg, Zabofloxacin 400mg
Drug
Lead sponsor
IASO Pharma Inc.
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
13
States / cities
Huntsville, Alabama • Toney, Alabama • Fort Myers, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated May 6, 2012 · Synced Jun 10, 2026, 6:15 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Fluad vs. Fluzone High-Dose Vaccine Effectiveness Among Adults ≥65 Years

NCT06029933
View directory record Official record
Conditions
Influenza, Community-acquired Pneumonia, Cardiovascular Events
Interventions
Adjuvanted Quadrivalent Inactivated Influenza Vaccine (aIIV4), High-Dose Quadrivalent Inactivated Influenza Vaccine (HD-IIV4)
Biological
Lead sponsor
Kaiser Permanente
Other
Eligibility
65 Years and older
Enrollment
960,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Oakland, California
Source: ClinicalTrials.gov public record
Updated Sep 7, 2023 · Synced Jun 10, 2026, 6:15 PM EDT
Not listed Phase 2 Interventional

Comparative Study of EDP-420 Versus Another Antibiotic in the Treatment of Community Acquired Pneumonia

NCT00270517
View directory record Official record
Conditions
Community Acquired Pneumonia
Interventions
EDP-420 / Duration of Treatment - 3 days, Telithromycin / Duration of Treatment - 7 days
Drug
Lead sponsor
Enanta Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 65 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Watertown, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 18, 2006 · Synced Jun 10, 2026, 6:15 PM EDT
Completed Phase 3 Interventional Results available

Extended Steroid in Use in Community Acquired Pneumonia (CAP)(e)

NCT01283009
View directory record Official record
Conditions
Community Acquired Respiratory Disease Syndrome
Interventions
Inactive Substance, Methylprednisolone
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
584 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
29
States / cities
Phoenix, Arizona • Loma Linda, California • Long Beach, California + 26 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2020 · Synced Jun 10, 2026, 6:15 PM EDT
Active, not recruiting No phase listed Observational

Reducing Antibiotic Use by Implementation of Stewardship in Primary and Urgent Care

NCT07217002
View directory record Official record
Conditions
Community Acquired Pneumonia (CAP), Sinusitis, Strep Pharyngitis, Acute Otitis Media (AOM)
Interventions
Online Educational Modules, Prescribing Feedback Reports, Clinical Decision Support, Live, hybrid in-person and online educational sessions
Other
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
6 Months to 12 Years
Enrollment
420 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Jun 10, 2026, 6:15 PM EDT
Completed Phase 3 Interventional Results available

Study Comparing the Safety and Efficacy of Cethromycin to Clarithromycin for the Treatment of Community-Acquired Pneumonia (CAP)

NCT00336505
View directory record Official record
Conditions
Pneumonia
Interventions
Cethromycin, Clarithromycin
Drug
Lead sponsor
Advanced Life Sciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
584 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
3
States / cities
Woodridge, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 25, 2010 · Synced Jun 10, 2026, 6:15 PM EDT